close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Mission Bio

News headline image
Mission Bio’s Tapestri Single Cell Multi-Omics Platform for Exploratory Biomarker Analysis Supports Myeloproliferative Neoplasms (MPNs) Data Presentation at ASH 2025
From Mission Bio
Via Business Wire
News headline image
Mission Bio Announces Single-Cell Targeted DNA + RNA Assay at ASH 2025, Closing the Mutation-to-Expression Gap in Cancer Research
From Mission Bio
Via Business Wire
News headline image
Mission Bio Appoints Dr. Zivjena Vucetic as Chief Medical Officer to Lead Clinical Adoption and Biopharma Partnerships
From Mission Bio
Via Business Wire
News headline image
Mission Bio Secures Equity Financing to Accelerate Single-Cell Tri-omics Platform Expansion
From Mission Bio
Via Business Wire
News headline image
Mission Bio Unveils Industry-First Single-Cell Genotype and Targeted Gene Expression Solution Aimed at Derisking Cancer Drug Clinical Development
From Mission Bio
Via Business Wire
News headline image
Nature Publication Shows Mission Bio's Tapestri® Platform Enables Real-Time, Single-Cell Tracking of Precancerous Clones Using Natural Epigenetic Markers
From Mission Bio
Via Business Wire
News headline image
Mission Bio and Integrated DNA Technologies Partner to Advance Single-Cell Precision in CRISPR Genome Editing Analysis
From Mission Bio
Via Business Wire
News headline image
Mission Bio Showcases Critical Insights Into Multiple Myeloma, AML MRD, CAR-T Safety & Integrated Single-Cell DNA and Fusion Profiling at the 2024 ASH Annual Meeting
From Mission Bio
Via Business Wire
News headline image
Mission Bio Partners With Top Researchers From University of Miami to Accelerate Early Relapse Detection & Treatment Selection of Multiple Myeloma Patients
From Mission Bio
Via Business Wire
News headline image
Mission Bio Launches Innovative Single-cell Genome Integrity Solution to Measure Whole Genome Copy Number Variation in Advanced Therapies and Tumor Samples
From Mission Bio
Via Business Wire
News headline image
Mission Bio’s Tapestri Platform Utilized for Advancements in Gene-Edited T-Cell Therapy
From Mission Bio
Via Business Wire
News headline image
Mission Bio Appoints Roman Haehn as Chief Commercial Officer to Drive Market Expansion
From Mission Bio
Via Business Wire
News headline image
Mission Bio Announces Launch of First Single-Cell Multiple Myeloma Multiomics Solution Aimed to Transform Translational Research and Therapy Development
From Mission Bio
Via Business Wire
News headline image
Mission Bio’s Tapestri Platform Unveils Insights into Targeted Therapy and Residual Disease Assessment for Multiple Myeloma
From Mission Bio
Via Business Wire
News headline image
Mission Bio's New Translocation Analysis Offers Insights into Critical Safety Assessment for Gene-Edited Cell Products
From Mission Bio
Via Business Wire
News headline image
Mission Bio Launches Sample Multiplexing for Tapestri to Unlock Critical Single-Cell Insights for Oncology and Genome Editing Markets
From Mission Bio
Via Business Wire
News headline image
Mission Bio Appoints Industry Veteran Brian Kim as CEO to Spearhead Single-Cell Genomic Solutions
From Mission Bio
Via Business Wire
News headline image
Mission Bio Announces Over 20 Presentations Demonstrating the Utility of Tapestri Across AML, Multiple Myeloma, and Lymphoma at the 2023 ASH Annual Meeting
From Mission Bio
Via Business Wire
News headline image
Mission Bio Announces High Precision Detection of Variants For Tapestri® Platform in NIST Genome Editing Consortium Initial Study
From Mission Bio
Via Business Wire
News headline image
Mission Bio’s Tapestri Platform Leveraged by Top Academic and Pharma Institutions to Pinpoint Disease-Driving Clones in Multiple Myeloma
From Mission Bio
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today